Canada Shingles Vaccine Market Size & Outlook, 2025-2030
Canada shingles vaccine market highlights
- The Canada shingles vaccine market generated a revenue of USD 110.1 million in 2023 and is expected to reach USD 244.5 million by 2030.
- The Canada market is expected to grow at a CAGR of 12.1% from 2024 to 2030.
- In terms of segment, shingrix was the largest revenue generating product in 2023.
- Shingrix is the most lucrative product segment registering the fastest growth during the forecast period.
Shingles vaccine market data book summary
| Market revenue in 2023 | USD 110.1 million |
| Market revenue in 2030 | USD 244.5 million |
| Growth rate | 12.1% (CAGR from 2023 to 2030) |
| Largest segment | Shingrix |
| Fastest growing segment | Shingrix |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Shingrix, Zostavax |
| Key market players worldwide | Merck & Co Inc, Skye Bioscience Inc Ordinary Shares, Green Cross Health Ltd, Barinthus Biotherapeutics PLC ADR, CanSino Biologics Inc Class H, GSK PLC, GeneOne Life Science |
Other key industry trends
- In terms of revenue, Canada accounted for 2.6% of the global shingles vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. shingles vaccine market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 6,596.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Shingles Vaccine Market Scope
Shingles Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| GeneOne Life Science | View profile | - | Soeul, Ch'ungch'ong-namdo, South Korea, Asia | https://www.genels.com/index.asp |
| CanSino Biologics Inc Class H | View profile | 1494 | 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, China, People's Republic of, | https://www.cansinotech.com |
| Barinthus Biotherapeutics PLC ADR | View profile | 130 | Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, United Kingdom, OX11 0DF | https://www.barinthusbio.com |
| Green Cross Health Ltd | View profile | - | 602 Great South Road, Ellerslie, Ground Floor, Building B, Millennium Centre, Auckland, NTL, New Zealand, 1051 | https://www.greencrosshealth.co.nz |
| Skye Bioscience Inc Ordinary Shares | View profile | 11 | 11250 El Camino Real, Suite 100, San Diego, CA, United States, 92130 | https://www.skyebioscience.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
Canada shingles vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to shingles vaccine market will help companies and investors design strategic landscapes.
Shingrix was the largest segment with a revenue share of 89.74% in 2024. Horizon Databook has segmented the Canada shingles vaccine market based on shingrix, zostavax covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Canada shingles vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Canada shingles vaccine market databook
-
Our clientele includes a mix of shingles vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada shingles vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Canada shingles vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
